September 4, 2024 03:48 PM EDT

Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says

Lei Lei Wu

News Reporter

Biogen on Wednesday said that an experimental, higher dose of its spinal muscular atrophy drug Spinraza met the primary endpoint of a clinical trial comparing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Updated: Bristol Myers touts LAG-3 strategy in lung cancer, but data caveats dampen excitement

Post-Hoc: Big promises built Moderna. They might also be its undoing

House passes Biosecure Act, sending Chinese biotech ban to Senate

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

High­er dose of Spin­raza helped spinal mus­cu­lar at­ro­phy pa­tients, Bio­gen says

News Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Higher dose of Spinraza helped spinal muscular atrophy patients, Biogen says